Dr. Jinzhang Chen 陈锦章
Chief Physician
Liver Tumor Center, Nanfang Hospital, Southern Medical University, Guangzhou
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Multidisciplinary treatment for liver cancer, cholangiocarcinoma, liver metastases, and pancreatic cancer. Expertise in targeted therapy, immunotherapy, HAIC, ablation, and combined local-systemic anticancer treatments.
Dr. Chen is a Chief Physician at the Liver Tumor Center, Nanfang Hospital, Southern Medical University. The doctor focuses on clinical oncology medical care, teaching, and research, with expertise in the comprehensive diagnosis and treatment of liver cancer and liver metastases.
Professional roles
- Member, Liver Disease Professional Committee, Chinese Research Hospital Association
- Deputy Leader, Hepatobiliary and Pancreatic Tumor Expert Group, China Hospital Association MTA
- Member, Liver Cancer Professional Committee, Chinese Medical Doctor Association
- Standing Committee Member, Liver Cancer MDT Professional Treatment Committee, Guangdong Provincial Liver Disease Society
Name order: in Chinese the family name comes first (Chen Jinzhang). Papers usually list the name as Jinzhang Chen or Chen J.
Selected publications
64 papers on PubMed matched by name and affiliation; 19 as first or senior author since 2016. Most recent first- or senior-author papers:
- Drug Metab Dispos, 2025 (senior author): Metabolomics and lipidomics predictor of survival in hepatocellular carcinoma patients receiving tyrosine kinase inhibitor and immune checkpoint inhibitor combination therapy. PubMed 41265377
- Liver Cancer, 2025 (senior author): Camrelizumab Combined with Lenvatinib and RALOX-Hepatic Arterial Infusion Chemotherapy for Unresectable Hepatocellular Carcinoma (Cal Era): A Prospective, Single-Arm, Phase II Trial. PubMed 40567389
- Int J Surg, 2025 (senior author): Comparison of the efficacy and safety of TACE-HAIC-MTTs-ICIs and TACE-MTTs-ICIs in the hepatocellular carcinoma: a prognostic analysis based on the dynamic changes of serum AFP. PubMed 40540455
- Liver Int, 2025 (senior author): Low-Level Viremia Impairs Efficacy of Immune Checkpoint Inhibitors in Unresectable Hepatocellular Carcinoma. PubMed 40078069
- Heliyon, 2024 (senior author): Cadonilimab (PD-1/CTLA-4) in combination with lenvatinib in unresectable hepatocellular carcinoma (uHCC): A retrospective real-world study. PubMed 39398001
- Discov Oncol, 2024 (senior author): Transarterial chemoembolization with/without immune checkpoint inhibitors plus tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a single center, propensity score matching real-world study. PubMed 38460053
- Int Immunopharmacol, 2023 (senior author): Tyrosine kinase inhibitors, immune checkpoint inhibitors combined with hepatic arterial infusion of oxaliplatin and raltitrexed versus oxaliplatin, 5-fluorouracil and leucovorin for intermediate and advanced hepatocellular carcinoma: A retrospective study. PubMed 37879230
- Zhonghua Gan Zang Bing Za Zhi, 2022 (senior author): [Application of liquid biopsy in early screening and recurrence prediction of hepatocellular carcinoma]. PubMed 36207938
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion